Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Olav Dalgard

Showing results (51-60 of 107) with videos related to

Pageof 11
Sort By:
Open Forum Infectious Diseases|April 20, 2026
Acute Respiratory Failure and Ventilatory Support in Hospitalized Adults With Viral Respiratory Infection: A Retrospective Cohort StudyKirill Neumann, Magrit Jarlsdatter Hovind, Jan-Erik Berdal, et al.
Nature Reviews. Gastroenterology & Hepatology|March 10, 2011
Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis CMark S Sulkowski, Curtis Cooper, Bela Hunyady, et al.
Plos One|January 31, 2018
Policy responses to hepatitis C in the Nordic countries: Gaps and discrepant reporting in the Hep-Nordic studyKelly Safreed-Harmon, Kristina L Hetherington, Soo Aleman, et al.
BMC Infectious Diseases|November 11, 2019
Prevalence of Viremic hepatitis C, hepatitis B, and HIV infection, and vaccination status among prisoners in Stockholm CountyCaroline Gahrton, Gabriel Westman, Karin Lindahl, et al.
Scandinavian Journal of Gastroenterology|June 26, 2013
Retreatment with peg-interferon and ribavirin in patients with chronic hepatitis C virus genotype 2 or 3 infection with prior relapseMartin Lagging, Karolina Rembeck, Mads Rauning Buhl, et al.
Trials|June 7, 2020
Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trialMagnus Nakrem Lyngbakken, Jan-Erik Berdal, Arne Eskesen, et al.
The International Journal on Drug Policy|March 1, 2021
Hepatitis C treatment and reinfection surveillance among people who inject drugs in a low-threshold program in Oslo, NorwayHåvard Midgard, Kjersti Ulstein, Øystein Backe, et al.
Viruses|June 27, 2024
Virologic Response and Reinfection Following HCV Treatment among Hospitalized People Who Inject Drugs: Follow-Up Data from the OPPORTUNI-C TrialKristian Braathen Malme, Kathrine Stene-Johansen, Ingvild Klundby, et al.
Harm Reduction Journal|October 13, 2021
Hepatitis C reinfection in former and active injecting drug users in BelgiumDana Busschots, Rob Bielen, Özgür M Koc, et al.
Nature Communications|October 21, 2020
A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kineticsMagnus Nakrem Lyngbakken, Jan-Erik Berdal, Arne Eskesen, et al.
Pageof 11

Showing results (51-60 of 107) with videos related to

Sort By:
Pageof 11
Open Forum Infectious Diseases|April 20, 2026
Acute Respiratory Failure and Ventilatory Support in Hospitalized Adults With Viral Respiratory Infection: A Retrospective Cohort StudyKirill Neumann, Magrit Jarlsdatter Hovind, Jan-Erik Berdal, et al.
Nature Reviews. Gastroenterology & Hepatology|March 10, 2011
Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis CMark S Sulkowski, Curtis Cooper, Bela Hunyady, et al.
Plos One|January 31, 2018
Policy responses to hepatitis C in the Nordic countries: Gaps and discrepant reporting in the Hep-Nordic studyKelly Safreed-Harmon, Kristina L Hetherington, Soo Aleman, et al.
BMC Infectious Diseases|November 11, 2019
Prevalence of Viremic hepatitis C, hepatitis B, and HIV infection, and vaccination status among prisoners in Stockholm CountyCaroline Gahrton, Gabriel Westman, Karin Lindahl, et al.
Scandinavian Journal of Gastroenterology|June 26, 2013
Retreatment with peg-interferon and ribavirin in patients with chronic hepatitis C virus genotype 2 or 3 infection with prior relapseMartin Lagging, Karolina Rembeck, Mads Rauning Buhl, et al.
Trials|June 7, 2020
Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trialMagnus Nakrem Lyngbakken, Jan-Erik Berdal, Arne Eskesen, et al.
The International Journal on Drug Policy|March 1, 2021
Hepatitis C treatment and reinfection surveillance among people who inject drugs in a low-threshold program in Oslo, NorwayHåvard Midgard, Kjersti Ulstein, Øystein Backe, et al.
Viruses|June 27, 2024
Virologic Response and Reinfection Following HCV Treatment among Hospitalized People Who Inject Drugs: Follow-Up Data from the OPPORTUNI-C TrialKristian Braathen Malme, Kathrine Stene-Johansen, Ingvild Klundby, et al.
Harm Reduction Journal|October 13, 2021
Hepatitis C reinfection in former and active injecting drug users in BelgiumDana Busschots, Rob Bielen, Özgür M Koc, et al.
Nature Communications|October 21, 2020
A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kineticsMagnus Nakrem Lyngbakken, Jan-Erik Berdal, Arne Eskesen, et al.
Pageof 11